Navetco National Veterinary Joint Stock Co
UUPCOM:VET13,200.00
VND
-300.00
(-2.22%)
ISIN
VN000000VET2
Return %
Stock
S&P 500
1Y
-20.00
14.20
3Y
-67.00
81.12
5Y
-80.30
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Ho Chi Minh City Vietnam
- IPO Date
- Dec 13, 2017
- Website
- navetco.com.vn
- Similar Companies
- Business
- Navetco National Veterinary Joint Stock Company is a Vietnam-based animal health company engaged in the research, development, manufacturing, and distribution of veterinary pharmaceuticals, vaccines, and aquaculture health products. The company operates through three primary business divisions: Veterinary Vaccines, Veterinary Pharmaceuticals, and Aquaculture & Nutritional Solutions. Its product portfolio comprises viral and bacterial vaccines for swine, poultry, and ruminants, including vaccines against African Swine Fever, porcine reproductive and respiratory syndrome (PRRS), avian influenza, Newcastle disease, classical swine fever, pasteurellosis, and rabies; pharmaceutical formulations, including antibiotics, antibacterials, anthelmintics, antiparasitics, anti-inflammatory agents, analgesics, and antipyretics; nutritional supplements and biosecurity solutions, including multivitamins, electrolyte preparations, mineral premixes, probiotics, and farm disinfectants and antiseptics; and specialized aquatic treatments and water conditioners. In addition to finished goods manufacturing, the company provides original equipment manufacturer (OEM) contract manufacturing, veterinary pathology testing, and laboratory diagnostic services for livestock farms, commercial agribusiness conglomerates, and veterinary healthcare providers. Founded in 1955 as the National Institute of Microbiology and Livestock Diseases and converted into a joint-stock company in 2013, Navetco is headquartered in Ho Chi Minh City, Vietnam, and operates World Health Organization Good Manufacturing Practice (GMP-WHO) certified production facilities in the Vietnam-Singapore Industrial Park in Binh Duong Province. The company distributes its products nationwide and exports to international markets across Southeast Asia, South Asia, and the Middle East, including Cambodia, Laos, Myanmar, and Bangladesh. In recent strategic developments, Navetco commercialized NAVET-ASFVAC, an African Swine Fever vaccine developed in partnership with the United States Department of Agriculture Agricultural Research Service, establishing one of the first commercially approved African Swine Fever vaccines globally. The company continues to advance international supply agreements and regulatory registrations for NAVET-ASFVAC across Southeast Asia and the Americas, including trial distributions in the Dominican Republic and the Philippines, while executing ongoing technological upgrades across its specialized vaccine and pharmaceutical production workshops to scale its export capabilities.